Drug Patent Watch

DECEMBER 26, 2024

The biopharmaceutical sector has made significant strides in developing and delivering effective drugs to improve health and combat diseases. However, the high cost of prescription drugs remains a significant barrier to access for many patients. One key solution to this issue lies in the role of generic drugs, which are significantly cheaper than branded products and can help reduce the financial burden on patients and the healthcare system.

Medicine 84

Medicine Generic Drugs Branding Engineer 84

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 26, 2024

(Nemes Laszlo/Science Photo Library/Getty Images) How we classify cancer and spot it in its earliest stages could need an urgent rethink: researchers have found that even some healthy women carry cells with the key hallmarks of breast cancer. These cells are known as aneuploid cells, and have an abnormal number of chromosomes.

Research 224

Research Clinical Trials Clinical Trials Trials 224

Pharmaceutical Technology

DECEMBER 26, 2024

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

Development 130

Development 130

XTalks

DECEMBER 26, 2024

Menarini Group has announced positive topline data from the Phase III BROADWAY and TANDEM clinical trials, evaluating obicetrapib and the fixed-dose combination of obicetrapib with ezetimibe. These trials aim to address a major challenge in cardiovascular disease: managing elevated low-density lipoprotein cholesterol (LDL-C) levels in patients at risk of heart disease.

Trials 52

Trials Life Science Clinical Trials Clinical Trials 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Pharmaceutical Technology

DECEMBER 26, 2024

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Marketing 130

Marketing 130

Pharmaceutical Commerce

DECEMBER 26, 2024

The top five episodes of our podcast in the year 2024, highlighted.

52

52

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 26, 2024

India needs to focus on the critical and often overlooked public health crisis posed by rare diseases (RDs) in India, while exploring lessons from global practices, said Prof. Ramaiah Muthyala, President and Founder, Indian Organization for Rare Diseases (IORD) and Research Associate Professor at the University of Minnesota, USA.

Research 185

Research Clinical Trials Clinical Trials Trials 185

Pharmaceutical Technology

DECEMBER 26, 2024

Allergen for Grass Pollen Allergy is under clinical development by Roxall Medizin and currently in Phase II for Grass Pollen Allergy.

Allergies 100

Allergies Clinical Development Development 100

Fierce Pharma

DECEMBER 26, 2024

As the life sciences industry prepares for a new administration, cutting edge technology and more, there are plenty of challenges in store for 2025and much to be optimistic about, too. Thats according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives across the global life sciences sphere that 75% of respondents are optimistic about the year ahead.

Life Science 96

Life Science 96

Pharmaceutical Technology

DECEMBER 26, 2024

Darigabat is under clinical development by Cerevel Therapeutics and currently in Phase II for Seizures.

Clinical Development 100

Clinical Development Development 100

Advertisement

Clinical Supply

Pharmaceutical Technology

DECEMBER 26, 2024

Nelivaptan is under clinical development by HMNC and currently in Phase II for Major Depressive Disorder.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 26, 2024

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Sarcomas.

Gene Therapy 100

Gene Therapy Gene Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 26, 2024

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

Gene Therapy 100

Gene Therapy Gene Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 26, 2024

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

Clinical Development 100

Clinical Development Development 100

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharmaceutical Technology

DECEMBER 26, 2024

KGYY-15 is under clinical development by Op-T-Mune and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes).

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 26, 2024

Lidocaine is under clinical development by MEDRx and currently in Pre-Registration for Postherpetic Neuralgia.

Clinical Development 100

Clinical Development Development 100

Pharmaceutical Technology

DECEMBER 26, 2024

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

Clinical Development 100

Clinical Development Development 100